Taken together, our results improve our understanding of how the HFD and the anti-obesity pharmacology influence tanycytes, which act not only as htNSCs but as metabolic regulators that control vascular permeability, leptin transport (Balland et al, 2014) and the entry of anti-obesity compounds such as Liraglutide to the hypothalamic parenchyma (Imbernon et al, 2022). The gene discussed is LEP; the disease is obesity disorder.